Clinical Study on Radiofrequency Ablation,Sorafenib and Interferon-α for Recurrent Hepatocellular Carcinoma after Curative Resection
xiao hua,xu ruocai,liu hanchun,li jianliang,yu zhiyuan,ou yangyongzhong,qiu xiaoxin,li qinglong,li yongguo,zhu haizhen,xie wenbiao,xie hailong,dan hanguo,liu jingshi,zuo chaohui
DOI: https://doi.org/10.16260/j.cnki.1009-2188.2015.05.004
2015-01-01
Abstract:Objective To investigate the clinical effects and safety of radiofrequency ablation( RFA),sorafenib and interferon-α( IFN-α) for patients with recurrent hepatocellular carcinoma( HCC) after curative resection. Methods The clinical data of 69 cases diagnosed with recurrent HBV-related HCC and underwent curative resection between January 2006 and December 2013 were analyzed retrospectively. The 69 patients were divided into IFN group( n = 34) and controlled group( n = 35) for treating recurrent HCC according to carry out IFN-α therapy or not. The complication rates,1-,3-and 5-year disease-free survival and overall survival rates were evaluated and compared between two groups. Results The clinicopathological parameters and adverse effects were similar between the two groups( P > 0. 05). Compared with the controlled group,the complication rate of IFN group had not statistic difference( 17. 6% vs. 17. 1%,P = 0. 96). The 1-,3-and 5-year disease-free survival rates were 56. 5%,21. 2% and 7. 6% in the IFN group respectively,and were 41. 7%,22. 7% and 5. 3% in the controlled group respectively,there was no statistic difference between two groups( P = 0. 99). Whereas the 1-,3- and 5-year overall survival rates were 87. 9%,45. 1%and 12. 0% respectively in the IFN group,those were better than 84. 3%,27. 4% and 6. 8% respectively in the controlled group( P = 0. 04). Conclusion The treatment of RFA therapy,sorafenib and IFN-α is safe and effective for recurrent HCC after curative resection,and it can improve the overall survival in patients with HBV-related HCC.